---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-034928"
form_type: "8-K"
ticker: "DWTX"
cik: "0001818844"
company_name: "Dogwood Therapeutics, Inc."
filed_at: "2026-03-26T23:59:59+00:00"
generated_at: "2026-05-15T08:52:18.266884+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Dogwood provides HALT-CINP trial update; $12.5M raised, SP16 IND filed

## Summary
- 145 patients recruited in Halneuron Phase 2b HALT-CINP study; final data expected fall 2026.
- Raised $12.5M in Q1 2026; combined with year-end cash extends runway through data release.
- Filed IND for SP16 IV (chemo-induced neuropathy); Phase 1b fully funded by NCI grant.
- Advanced synthetic Halneuron formulation for Phase 3; aims to cut costs and boost yields.

## SEC filing metadata
- accession: 0001104659-26-034928
- form_type: 8-K
- ticker: DWTX
- cik: 0001818844
- company_name: Dogwood Therapeutics, Inc.
- filed_at: 2026-03-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818844/000110465926034928/0001104659-26-034928-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818844/000110465926034928/dwtx-20260326x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-034928
- JSON: https://secwatch.observer/filing/0001104659-26-034928.json
- Plain text: https://secwatch.observer/filing/0001104659-26-034928.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.